[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 6, 2008

Universal Access to HIV/AIDS Treatment: Promise and Problems

Author Affiliations

Author Affiliations: Department of Public Health, University of Oxford, Oxford, United Kingdom.

JAMA. 2008;300(5):573-575. doi:10.1001/jama.300.5.573

The 21st century has witnessed unprecedented increases in funding for global health, driven mainly by efforts to address the HIV/AIDS epidemic. The US President's Emergency Plan for AIDS Relief (PEPFAR) is the largest single donor, having allocated approximately $13 billion for AIDS prevention, treatment, and care in developing countries and contributed $3 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria since the plan's inception in 2003.1 For the next 5 years, the president is seeking a $30 billion appropriation for PEPFAR while Congress is proposing to increase the appropriation to $50 billion and add funding for malaria and tuberculosis programs. In contrast, the World Health Organization (WHO) smallpox eradication program, conducted from 1967 through 1979, cost less than $2 billion (adjusted for inflation).2